Korea’s Biopharma Regulatory Reform Push To Focus On Innovation, Streamlining
Multiple Areas Targeted
Executive Summary
South Korea is aiming to implement a broad range of regulatory reform steps to better compete with global rivals and speed up patient access to novel therapies.
You may also be interested in...
McKinsey Exec On Scaling The Rising Compliance Bar, Supply Chain Resilience
McKinsey & Company's senior partner Vikas Bhadoria, in this second instalment of a wide-ranging interview with Scrip, talks about 'smart quality', the compliance trajectory of Indian firms and also measures by Korea and China to accelerate biosimilar development and innovation.
New Korea Commission Needs Status To Function As Control Tower: Industry
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
Global Health Leaders Highlight Pandemic Preparedness
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.